Overview
CRBP market data
Price History
CRBP price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.64 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.57 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -2,838.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $7.12 – $20.56 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $185.1M · P/B 0.97 · P/S 119.42.
Company News
Corbus Pharmaceuticals Enters Open Market Sale Agreement With Jefferies; Co. To Offer And Sell Common Stock Up To $127.50M Through JefferiesBenzinga · Aug 7, 2026, 8:46 PM
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $48Benzinga · Aug 7, 2026, 1:58 PM
HC Wainwright & Co. Maintains Buy on Corbus Pharmaceuticals, Lowers Price Target to $35Benzinga · Aug 7, 2026, 1:09 PM
Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) EstimateBenzinga · Aug 6, 2026, 12:32 PM
8-K filing — Corbus Pharmaceuticals Holdings, Inc. (CRBP)SEC EDGAR · Aug 6, 2026, 12:15 PM
Corbus Pharmaceuticals' Last Participant Completes Last Clinical Visit In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat ObesityBenzinga · Aug 4, 2026, 12:33 PM
Corbus Pharmaceuticals Receives FDA Clearance To Start Its TEMPO-1 Registrational StudyOf CRB-701, A Nectin-4 Targeted Antibody Drug Conjugate In Second-Line Oropharyngeal Squamous Cell CarcinomaBenzinga · Jul 28, 2026, 12:03 PM
Mizuho Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $34Benzinga · Jun 23, 2026, 3:10 PM
Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $52Benzinga · Jun 17, 2026, 1:35 PM
Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30Benzinga · May 27, 2026, 1:35 PM